Therapeutic potential of breakers of advanced glycation end product-protein crosslinks - PubMed (original) (raw)
Review
Therapeutic potential of breakers of advanced glycation end product-protein crosslinks
Sara Vasan et al. Arch Biochem Biophys. 2003.
Abstract
Long-lived structural proteins, collagen and elastin, undergo continual non-enzymatic crosslinking during aging and in diabetic individuals. This abnormal protein crosslinking is mediated by advanced glycation end products (AGEs) generated by non-enzymatic glycosylation of proteins by glucose. The AGE-derived protein crosslinking of structural proteins contributes to the complications of long-term diabetes such as nephropathy, retinopathy, and neuropathy. AGE-crosslinks have also been implicated in age-related cardiovascular diseases. Potential treatment strategies for these AGE-derived complications include prevention of AGE-formation and breaking of the existing AGE-crosslinks. The therapeutic potential of the AGE-inhibitor, pimagedine (aminoguanidine), has been extensively investigated in animal models and in Phase 3 clinical trials. This review presents the pre-clinical and clinical studies using ALT-711, a highly potent AGE-crosslink breaker that has the ability to reverse already-formed AGE-crosslinks. Oral administration of ALT-711 has resulted in a rapid improvement in the elasticity of stiffened myocardium in experimental animals. Topical administration of ALT-711 was effective in improving the skin hydration of aged rats. The therapeutic potential of crosslink breakers for cardiovascular complications and dermatological alterations associated with aging and diabetes is discussed.
Similar articles
- Crosslink breakers: a new approach to cardiovascular therapy.
Susic D, Varagic J, Ahn J, Frohlich ED. Susic D, et al. Curr Opin Cardiol. 2004 Jul;19(4):336-40. doi: 10.1097/01.hco.0000127135.73849.4f. Curr Opin Cardiol. 2004. PMID: 15218393 Review. - Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links.
Vasan S, Foiles PG, Founds HW. Vasan S, et al. Expert Opin Investig Drugs. 2001 Nov;10(11):1977-87. doi: 10.1517/13543784.10.11.1977. Expert Opin Investig Drugs. 2001. PMID: 11772301 Review. - AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats.
Yang S, Litchfield JE, Baynes JW. Yang S, et al. Arch Biochem Biophys. 2003 Apr 1;412(1):42-6. doi: 10.1016/s0003-9861(03)00015-8. Arch Biochem Biophys. 2003. PMID: 12646266 - Pimagedine: a novel therapy for diabetic nephropathy.
Abdel-Rahman E, Bolton WK. Abdel-Rahman E, et al. Expert Opin Investig Drugs. 2002 Apr;11(4):565-74. doi: 10.1517/13543784.11.4.565. Expert Opin Investig Drugs. 2002. PMID: 11922864 Review. - An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness.
Asif M, Egan J, Vasan S, Jyothirmayi GN, Masurekar MR, Lopez S, Williams C, Torres RL, Wagle D, Ulrich P, Cerami A, Brines M, Regan TJ. Asif M, et al. Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2809-13. doi: 10.1073/pnas.040558497. Proc Natl Acad Sci U S A. 2000. PMID: 10706607 Free PMC article.
Cited by
- Advanced Glycation End Products in Health and Disease.
Reddy VP, Aryal P, Darkwah EK. Reddy VP, et al. Microorganisms. 2022 Sep 15;10(9):1848. doi: 10.3390/microorganisms10091848. Microorganisms. 2022. PMID: 36144449 Free PMC article. Review. - Effect of the age cross-link breaker alagebrium on anterior segment physiology, morphology, and ocular age and rage.
Kiland JA, Gabelt BT, Tezel G, Lütjen-Drecoll E, Kaufman PL. Kiland JA, et al. Trans Am Ophthalmol Soc. 2009 Dec;107:146-58. Trans Am Ophthalmol Soc. 2009. PMID: 20126491 Free PMC article. - Attenuation of Glucose-Induced Myoglobin Glycation and the Formation of Advanced Glycation End Products (AGEs) by (R)-α-Lipoic Acid In Vitro.
Ghelani H, Razmovski-Naumovski V, Pragada RR, Nammi S. Ghelani H, et al. Biomolecules. 2018 Feb 8;8(1):9. doi: 10.3390/biom8010009. Biomolecules. 2018. PMID: 29419812 Free PMC article. - Remodeling of the rat distal colon in diabetes: function and ultrastructure.
Siegman MJ, Eto M, Butler TM. Siegman MJ, et al. Am J Physiol Cell Physiol. 2016 Jan 15;310(2):C151-60. doi: 10.1152/ajpcell.00253.2015. Epub 2015 Nov 11. Am J Physiol Cell Physiol. 2016. PMID: 26561639 Free PMC article. - The effect of the microscopic and nanoscale structure on bone fragility.
Ruppel ME, Miller LM, Burr DB. Ruppel ME, et al. Osteoporos Int. 2008 Sep;19(9):1251-65. doi: 10.1007/s00198-008-0579-1. Epub 2008 Mar 4. Osteoporos Int. 2008. PMID: 18317862 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources